|
Synonyms: BIW-8405 | Fasenra® | KHK4563 | MEDI-563
benralizumab is an approved drug (FDA (2017), EMA (2018))
Compound class:
Antibody
Comment: Benralizumab is a humanized, afucosylated mAb targeting the IL5Rα which is expressed by cells of the eosinophil lineage. The antibody is afucosylated (ie has fucose containing oligosaccharide side-chains removed) to improve structure, stability, and biological function.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB link. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖
View more information in the IUPHAR Pharmacology Education Project: benralizumab |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (FDA (2017), EMA (2018)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 9233 | benralizumab |
| Synonyms |
| BIW-8405 | Fasenra® | KHK4563 | MEDI-563 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 334 |
| Other databases | |
| ChEMBL Ligand | CHEMBL1742991 |
| GtoPdb PubChem SID | 223366009 |
| Search PubMed clinical trials | benralizumab |
| Search PubMed titles | benralizumab |
| Search PubMed titles/abstracts | benralizumab |
| Wikipedia | Benralizumab |
